Abstract

Aging is a critical risk factor in idiopathic pulmonary fibrosis (IPF). Dysfunction and loss of type 2 alveolar epithelial cells (AEC2s) with failed regeneration is a seminal causal event in the pathogenesis of IPF, although the precise mechanisms for their regenerative failure and demise remain unclear. To systematically examine the genomic program changes of AEC2s in aging and after lung injury, we performed unbiased single-cell RNA-seq analyses of lung epithelial cells from uninjured or bleomycin-injured young and old mice, as well as from lungs of IPF patients and healthy donors. We identified three AEC2 subsets based on their gene signatures. Subset AEC2-1 mainly exist in uninjured lungs, while subsets AEC2-2 and AEC2-3 emerged in injured lungs and increased with aging. Functionally, AEC2 subsets are correlated with progenitor cell renewal. Aging enhanced the expression of the genes related to inflammation, stress responses, senescence, and apoptosis. Interestingly, lung injury increased aging-related gene expression in AEC2s even in young mice. The synergistic effects of aging and injury contributed to impaired AEC2 recovery in aged mouse lungs after injury. In addition, we also identified three subsets of AEC2s from human lungs that formed three similar subsets to mouse AEC2s. IPF AEC2s showed a similar genomic signature to AEC2 subsets from bleomycin-injured old mouse lungs. Taken together, we identified synergistic effects of aging and AEC2 injury in transcriptomic and functional analyses that promoted fibrosis. This study provides new insights into the interactions between aging and lung injury with interesting overlap with diseased IPF AEC2 cells.

Data availability

The raw datasets of single cell RNA-seq of mouse and human epithelial cells are under GSE157995 and GSE157996, respectively.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. jiurong Liang

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  2. Guanling Huang

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  3. Xue Liu

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  4. Ningshan Liu

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  5. Forough Taghavifar

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  6. Kristy Dai

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  7. Changfu Yao

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  8. Nan Deng

    Genomics Core, Cedars-Sinai Medical Center, los Angeles, United States
    Competing interests
    No competing interests declared.
  9. Yizhou Wang

    Genomics Core, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  10. Peter Chen

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  11. Cory Hogaboam

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  12. Barry R Stripp

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  13. William C Parks

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  14. Paul W Noble

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    For correspondence
    paul.noble@cshs.org
    Competing interests
    Paul W Noble, Senior editor, eLife.
  15. Dianhua Jiang

    Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States
    For correspondence
    dianhua.jiang@cshs.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4508-3829

Funding

National Institute on Aging (R0-1AG078655)

  • jiurong Liang

National Heart, Lung, and Blood Institute (R35-HL150829)

  • Paul W Noble

National Heart, Lung, and Blood Institute (R01-HL060539)

  • Paul W Noble

National Heart, Lung, and Blood Institute (P01-HL108793)

  • Dianhua Jiang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Monica Kraft, Icahn School of Medicine at Mount Sinai, United States

Ethics

Animal experimentation: Animals and Study ApprovalAll mouse maintenance and procedures were done under the guidance of the Cedars-Sinai Medical Center Institutional Animal Care and Use Committee (IACUC008529) in accordance with institutional and regulatory guidelines. All mice were housed in a pathogen-free facility at Cedars-Sinai. Eight to 12 weeks old (young) and 18 to 24 months old (aged) wild-type C57Bl/6J mice were obtained from The Jackson Laboratory and housed in the institution facility at least 2 weeks before experiments.

Human subjects: Information of human subjects, Human Lung Tissue, and Study ApprovalThe use of human tissues for research was approved by the Institutional Review Board (IRB) of Cedars-Sinai and was under the guidelines outlined by the IRB (Pro00032727). Informed consent was obtained from each subject. The human samples used in the studies are age matched between IPF and healthy donors. The median age is 60 for healthy donors and 66 for IPF patients. We are aware to get the best age-matched samples within each experiment.

Version history

  1. Preprint posted: July 30, 2020 (view preprint)
  2. Received: December 7, 2022
  3. Accepted: June 13, 2023
  4. Accepted Manuscript published: June 14, 2023 (version 1)
  5. Version of Record published: June 26, 2023 (version 2)

Copyright

© 2023, Liang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,381
    views
  • 157
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. jiurong Liang
  2. Guanling Huang
  3. Xue Liu
  4. Ningshan Liu
  5. Forough Taghavifar
  6. Kristy Dai
  7. Changfu Yao
  8. Nan Deng
  9. Yizhou Wang
  10. Peter Chen
  11. Cory Hogaboam
  12. Barry R Stripp
  13. William C Parks
  14. Paul W Noble
  15. Dianhua Jiang
(2023)
Reciprocal interactions between alveolar progenitor dysfunction and aging promote lung fibrosis
eLife 12:e85415.
https://doi.org/10.7554/eLife.85415

Share this article

https://doi.org/10.7554/eLife.85415

Further reading

    1. Cell Biology
    2. Neuroscience
    Toshiharu Ichinose, Shu Kondo ... Hiromu Tanimoto
    Research Article

    Multicellular organisms are composed of specialized cell types with distinct proteomes. While recent advances in single-cell transcriptome analyses have revealed differential expression of mRNAs, cellular diversity in translational profiles remains underinvestigated. By performing RNA-seq and Ribo-seq in genetically defined cells in the Drosophila brain, we here revealed substantial post-transcriptional regulations that augment the cell-type distinctions at the level of protein expression. Specifically, we found that translational efficiency of proteins fundamental to neuronal functions, such as ion channels and neurotransmitter receptors, was maintained low in glia, leading to their preferential translation in neurons. Notably, distribution of ribosome footprints on these mRNAs exhibited a remarkable bias toward the 5′ leaders in glia. Using transgenic reporter strains, we provide evidence that the small upstream open-reading frames in the 5’ leader confer selective translational suppression in glia. Overall, these findings underscore the profound impact of translational regulation in shaping the proteomics for cell-type distinction and provide new insights into the molecular mechanisms driving cell-type diversity.

    1. Cancer Biology
    2. Cell Biology
    Camille Dantzer, Justine Vaché ... Violaine Moreau
    Research Article

    Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which oncogenic ß-catenin affects immune surveillance remain unclear. Herein, we highlighted the involvement of ß-catenin in the regulation of the exosomal pathway and, by extension, in immune/cancer cell communication in hepatocellular carcinoma (HCC). We showed that mutated ß-catenin represses expression of SDC4 and RAB27A, two main actors in exosome biogenesis, in both liver cancer cell lines and HCC patient samples. Using nanoparticle tracking analysis and live-cell imaging, we further demonstrated that activated ß-catenin represses exosome release. Then, we demonstrated in 3D spheroid models that activation of β-catenin promotes a decrease in immune cell infiltration through a defect in exosome secretion. Taken together, our results provide the first evidence that oncogenic ß-catenin plays a key role in exosome biogenesis. Our study gives new insight into the impact of ß-catenin mutations on tumor microenvironment remodeling, which could lead to the development of new strategies to enhance immunotherapeutic response.